Beranda › Sindrom Sjogren › North Carolina
Uji klinis Sindrom Sjogren di North Carolina
6 studi untuk Sindrom Sjogren mencari peserta di lokasi di North Carolina.
Kota di North Carolina
Teks studi resmi (Bahasa Inggris)
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- On Site Clinical Solutions Llc, Charlotte
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07621809Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
- Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT07404865AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Charlotte, Charlotte
- Artiva Investigational Site Charlotte, Charlotte
- Artiva Investigational Site Statesville, Statesville
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT06991114A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
- Arthritis and Osteoporosis Consultants of The Carolinas - Charlotte - 1918 Randolph Rd, Charlotte
- Duke Early Phase Clinical Research Unit - PPDS, Durham
- Onsite Clinical Solutions, LLC - Salisbury, Salisbury
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Apr 2026 · NCT06747949Maternal Autoimmune Disease Research Alliance (MADRA) Registry
- Duke University, Durham
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Semua usia · Wanita · Diperbarui 8 Jan 2026 · NCT03276923The Myelin Disorders Biorepository Project
- Atrium Health Wake Forest Baptist, Winston-Salem
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 23 Okt 2025 · NCT03047369Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.